The crystal structure of a human endogenous reverse transcriptase has similarities to HIV reverse transcriptase, a well-known tractable drug target, which will help design drugs to treat cancer and ...

Gilead Sciences, Inc. GILD and partner Merck MRK announced positive data from two late-stage studies, ISLEND-1 and ISLEND-2, ...

The crystal structure of a human endogenous reverse transcriptase has similarities to HIV reverse transcriptase, a well-known tractable drug target, which will help design drugs to treat cancer and ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--ROME Therapeutics, a biotechnology company harnessing the power of the dark genome for drug development, today announced a new publication in The Proceedings of the ...

Many cancers exhibit high levels of the reverse transcriptase enzyme. Single-agent lamivudine, a reverse transcriptase inhibitor, stopped disease progression in over 25% of patients with fourth-line ...

Meeting UNAIDS’ “95/95/95” targets for 2025—95% of people with HIV knowing their status, 95% of those who know their status on treatment, and 95% of people on treatment having a suppressed viral ...

Gilead & Merck announce positive topline results from two phase 3 studies evaluating islatravir/lenacapavir, an oral once-weekly HIV treatment: Foster City, California Wednesday, ...

Gilead and Merck announce positive phase 3 results for once-weekly oral islatravir/lenacapavir, demonstrating noninferiority in virologically suppressed HIV.

The combination of islatravir and lenacapavir targets multiple stages of HIV-1 replication, potentially offering people with ...

Gilead Sciences, Inc. GILD has a market-leading HIV franchise, led by flagship HIV therapies — Biktarvy for treatment and ...